Downregulation of the IRF1 gene inhibited mtDNA synthesis, attenuating AIM2 inflammasome activation and pyroptosis, providing a potential therapeutic target for NAFLD [158]. Here, AIM2 is linked to metabolic dysfunction-associated steatotic liver disease.